<PRE>                                                                                                                             
03 FEB 2012 05:50                     LEUK ACCRUAL REPORT - OPEN and recently closed STUDIES                                      
                                                                                                                                  
                                         O                                               REGS. REGS. REGS. REGS. REGS.            
                                       R P                                                LAST  LAST  LAST  LAST  LAST  # of  # of
                                       E E                                   ACCR. TOTAL    12     6     3    30     7  ACT.  CURR
STUDY                                  G N ARM                                GOAL REGS. Month Month Month  DAYS  DAYS INSTs  IRBs
-------------------------------------- - - --------------------------------- ----- ----- ----- ----- ----- ----- ----- ----- -----
S0521-APL,Low/Int Risk, Maint vs Obs   1 N 1  ATRA + ARA-C + Daunorubicin      550   105     0     0     0     0     0            
                                                                                   ----- ----- ----- ----- ----- -----            
                                                                                     105     0     0     0     0     0            
                                                                                                                                  
                                       * *                                   ***** -----                               ***** *****
                                       s                                             105                                          
                                       2 Y 2  Consolidation                           92     0     0     0     0     0            
                                                                                   ----- ----- ----- ----- ----- -----            
                                                                                      92     0     0     0     0     0            
                                                                                                                                  
                                       * *                                   ***** -----                               ***** *****
                                       s                                              92                                          
                                       3 Y 3  ATRA + 6MP + MTX                 440    41     1     0     0     0     0            
                                           4  Observation                             27     0     0     0     0     0            
                                                                                   ----- ----- ----- ----- ----- -----            
                                                                                      68     1     0     0     0     0            
                                                                                                                                  
                                       * *                                   ***** -----                               ***** *****
                                       s                                              68                                          
                                       4 N 5  Gemtuzumab Ozogamicin                    1     0     0     0     0     0            
                                                                                   ----- ----- ----- ----- ----- -----            
                                                                                       1     0     0     0     0     0            
                                                                                                                                  
                                       * *                                   ***** -----                               ***** *****
                                       s                                               1                                          
                                                                                                                                  
S0535-APL,High Risk, ATRA/arsenic/GO   1 Y 1  ATRA + G.O. + Arsenic             77    54    19    12     5     3     0   130    52
                                                                                   ----- ----- ----- ----- ----- -----            
                                                                                      54    19    12     5     3     0            
                                                                                                                                  
                                       * *                                   ***** -----                               ***** *****
                                       s                                              54                                          
                                       2 Y 2  Consolidation                           39    10     6     4     2     0   130    52
                                                                                   ----- ----- ----- ----- ----- -----            
                                                                                      39    10     6     4     2     0            
                                                                                                                                  
                                       * *                                   ***** -----                               ***** *****
                                       s                                              39                                          
                                       3 Y 3  ATRA + 6-MP + MTX                       24     4     2     2     2     0   130    52
                                                                                   ----- ----- ----- ----- ----- -----            
                                                                                      24     4     2     2     2     0            
                                                                                                                                  
                                       * *                                   ***** -----                               ***** *****
                                       s                                              24                                          
                                                                                                                                  
S0703-AML, AGE 60+, AZACITIDINE G.O.   3 Y 3  Azacitidine                      139    24     3     3     2     1     0   163    53
                                                                                   ----- ----- ----- ----- ----- -----            
                                                                                      24     3     3     2     1     0            
                                                                                                                                  
                                       * *                                   ***** -----                               ***** *****
                                       s                                              24                                          
                                                                                                                                  
S0703-AML, age 60+, Azacitidine G.O.   1 Y 1  Hydroxyurea/Azacitidine/G.O.     153   132    42    26    16    11     3   163    53
                                                                                   ----- ----- ----- ----- ----- -----            
                                                                                     132    42    26    16    11     3            
                                                                                                                                  
                                       * *                                   ***** -----                               ***** *****
                                       s                                             132                                          
                                       2 Y 2  Azacitidine/G.O.                 139    33     8     5     3     2     0   163    53
                                                                                   ----- ----- ----- ----- ----- -----            
                                                                                      33     8     5     3     2     0            
                                                                                                                                  
                                       * *                                   ***** -----                               ***** *****
                                       s                                              33                                          
                                                                                                                                  
S0805-PH+ ALL, DASATINIB/CVAD +/- BMT  4 Y 4  Dasatinib                                4     3     3     1     1     1    93    39
                                                                                   ----- ----- ----- ----- ----- -----            
                                                                                       4     3     3     1     1     1            
                                                                                                                                  
                                       * *                                   ***** -----                               ***** *****
                                       s                                               4                                          
                                                                 
<PRE>                                                                                                                             
03 FEB 2012 05:50                     LEUK ACCRUAL REPORT - OPEN and recently closed STUDIES                                      
                                                                                                                                  
                                         O                                               REGS. REGS. REGS. REGS. REGS.            
                                       R P                                                LAST  LAST  LAST  LAST  LAST  # of  # of
                                       E E                                   ACCR. TOTAL    12     6     3    30     7  ACT.  CURR
STUDY                                  G N ARM                                GOAL REGS. Month Month Month  DAYS  DAYS INSTs  IRBs
-------------------------------------- - - --------------------------------- ----- ----- ----- ----- ----- ----- ----- ----- -----
                                                                                                                                  
S0805-Ph+ ALL, Dasatinib/CVAD +/- BMT  1 Y 1  Induction/Consolidation           94    23    20    12     8     2     0    93    39
                                                                                   ----- ----- ----- ----- ----- -----            
                                                                                      23    20    12     8     2     0            
                                                                                                                                  
                                       * *                                   ***** -----                               ***** *****
                                       s                                              23                                          
                                       3 Y 3  Allo stem cell transplant         37     8     7     4     3     3     1    93    39
                                                                                   ----- ----- ----- ----- ----- -----            
                                                                                       8     7     4     3     3     1            
                                                                                                                                  
                                       * *                                   ***** -----                               ***** *****
                                       s                                               8                                          
                                                                                                                                  
S0910-Rel ph-,B-ALL,Epratuzumab+Cy+Clo 1 Y 1  ARA-C+Clofarabine+Epratruzumab    35    25    21    13     8     2     0   119    35
                                                                                   ----- ----- ----- ----- ----- -----            
                                                                                      25    21    13     8     2     0            
                                                                                                                                  
                                       * *                                   ***** -----                               ***** *****
                                       s                                              25                                          
                                                                                                                                  
S0919-Rel AML: Pravastatin+Ida+Ara-C   1 Y 1  Pravastatin+Idarubicin+Ara-C      55    25    14     8     4     0     0   113    36
                                                                                   ----- ----- ----- ----- ----- -----            
                                                                                      25    14     8     4     0     0            
                                                                                                                                  
                                       * *                                   ***** -----                               ***** *****
                                       s                                              25                                          
                                       2 Y 2  Pravastatin+Idarubicin+Ara-C             7     4     2     2     0     0   113    36
                                                                                   ----- ----- ----- ----- ----- -----            
                                                                                       7     4     2     2     0     0            
                                                                                                                                  
                                       * *                                   ***** -----                               ***** *****
                                       s                                               7                                          
                                                                                                                                  
C10403-ALL <40 yrs-Ped,Chemo. Regimen  1 Y 1  Sequential Chemotherapy          300    65    25    13     7     3     1   142    59
                                                                                   ----- ----- ----- ----- ----- -----            
                                                                                      65    25    13     7     3     1            
                                                                                                                                  
                                       * *                                   ***** -----                               ***** *****
                                       s                                              65                                          
                                                                                                                                  
C10404-CLL, Flu/Rituxan combinations   1 Y 1  Flu/Rituximab                    300     9     6     2     2     1     0   121    55
                                           2  Flu/Rituximab/Lenalidomide               5     2     1     1     0     0            
                                           3  Flu/Cy/Rituximab                        12     6     3     2     1     0            
                                                                                   ----- ----- ----- ----- ----- -----            
                                                                                      26    14     6     5     2     0            
                                                                                                                                  
                                       * *                                   ***** -----                               ***** *****
                                       s                                              26                                          
                                                                                                                                  
E1908-Tx of PCL Leuk w/Alemtuz, Ritux  1 E Total Registrations                         1     1     1     0     0     0    45    22
                                                                                   ----- ----- ----- ----- ----- -----            
                                                                                       1     1     1     0     0     0            
                                                                                                                                  
                                       * *                                   ***** -----                               ***** *****
                                       s                                               1                                          
                                                                                                                                  
E2905-MDS, Len vs Len + Epo            1 E Total Registrations                        21     9     4     2     2     1   148    83
                                                                                   ----- ----- ----- ----- ----- -----            
                                                                                      21     9     4     2     2     1            
                                                                                                                                  
                                       * *                                   ***** -----                               ***** *****
                                       s                                              21                                          
                                                                                                                                  







                                                                 

23 rows selected.

03 FEB 2012 05:50                             LEUK Open Studies with No Registrations                                             
                                                                                                                                  
Study                                    Registration/Phase                  Open Date                                            
---------------------------------------- ----------------------------------- ---------                                            
S0805 Ph+ ALL, Dasatinib/CVAD +/- BMT    2 Maintenance                       01-Sep-09                                            


















                                                                 

1 row selected.


no rows selected

</PRE><A HREF="http://www.swogstat.org" NAME="SWOG StatCtr Home Page">SWOG StatCtr Home Page</A>                                  

1 row selected.